Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mechanistic Models: Overview of Compartment Models01:21

Mechanistic Models: Overview of Compartment Models

360
Mechanistic models, a category encompassing both physiological and compartmental modeling, differ from empirical models' approaches to incorporating known factors about the systems being modeled. Empirical models describe data with minimal assumptions, while mechanistic models aim to provide a robust description of available data by specifying assumptions and integrating known factors about the system. Compartmental analysis is a key example of a mechanistic model in pharmacokinetics and...
360
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

493
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
493
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

1.9K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.9K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

245
Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least...
245
Quantitative Aspects of Drug-Receptor Interaction01:30

Quantitative Aspects of Drug-Receptor Interaction

1.7K
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GABA: The Peacekeeper Neurotransmitter-Gut-microbiota Derived Origins and Salivary Biomarker Detection Using Elisa.

Annals of neurosciences·2026
Same author

Performance of Trigger Tools in Identifying Adverse Drug Events in Emergency Intensive Care Unit: A Prospective Observational Study.

Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine·2025
Same author

Prevalence of <i>CYP2C19</i> Poor Metabolisers 
Among South Indian Psychiatric Patients: 
A Pharmacogenetic Perspective Toward 
Precision Psychopharmacology.

Annals of neurosciences·2025
Same author

Molecular Docking Studies of <i>Scutellaria baicalensis</i> Targeting HIV Co-Receptor CXCR4.

Current HIV research·2025
Same author

Carbamazepine-induced Stevens-Johnson Syndrome: A Case Report with Review of the Literature.

Current drug safety·2024
Same author

Dosage Optimization of Lamotrigine in Pregnancy: A Pharmacometric Approach Using Modeling and Simulation.

Journal of clinical pharmacology·2022

Related Experiment Video

Updated: Jan 16, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K

Beyond the Forest Plot: Redefining Model-Based Meta-Analysis as a Quantitative Engine for Model-Informed Drug

Bhavatharini Sukumaran1, Rinu Mary Xavier1, Aswathy Vs2

  • 1Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India.

Drug Development Research
|January 15, 2026
PubMed
Summary
This summary is machine-generated.

Model-Based Meta-analysis (MBMA) enhances drug development by integrating pharmacometric modeling with traditional meta-analysis. This advanced method provides predictive insights for dose selection and treatment effects, overcoming limitations of standard evidence synthesis.

Keywords:
Bayesian hierarchical modelsModel‐Based Meta‐Analysis (MBMA)Model‐Informed Drug Development (MIDD)dose‐response modelingpharmacometrics

More Related Videos

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
08:47

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation

Published on: September 28, 2022

2.3K
A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research
09:35

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

18.3K

Related Experiment Videos

Last Updated: Jan 16, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K
Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
08:47

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation

Published on: September 28, 2022

2.3K
A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research
09:35

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

18.3K

Area of Science:

  • Pharmacometrics
  • Clinical Trial Methodology
  • Evidence Synthesis

Background:

  • Traditional meta-analysis has limitations in drug development, particularly for dose selection and time-course dynamics.
  • Model-Based Meta-analysis (MBMA) combines pharmacometric modeling with meta-analysis to address these limitations.

Purpose of the Study:

  • To critically assess MBMA as a quantitative tool for model-informed drug development (MIDD).
  • To demystify MBMA's methodology, practical applications, and its distinction from traditional meta-analysis.

Main Methods:

  • Summarizing and synthesizing major MBMA techniques, including nonlinear mixed-effects modeling and Bayesian hierarchical models.
  • Discussing model estimation, validation, and uncertainty quantification.
  • Reviewing therapeutic area applications and regulatory considerations.

Main Results:

  • MBMA offers predictive information by considering dose-response relationships, longitudinal effects, and between-study heterogeneity.
  • MBMA aids in dose optimization, efficacy comparison, pediatric extrapolation, and clinical trial design.
  • MBMA translates heterogeneous clinical data into actionable insights for drug development.

Conclusions:

  • MBMA is a valuable, though underutilized, technique in model-informed drug development.
  • MBMA provides a significant advancement over traditional meta-analysis for quantitative decision-making.
  • MBMA is crucial for leveraging clinical data across the drug development lifecycle.